#United States #New York #Pomerantz LLP #PepGen Inc. #FDA Hold

Investigation Overview

Pomerantz LLP, a prominent law firm known for its expertise in securities class actions, has initiated an investigation on behalf of investors in PepGen Inc. (NASDAQ: PEPG). This investigation emerges in light of serious concerns regarding possible securities fraud and other unlawful business practices that may involve PepGen's management. Investors who are affected are urged to reach out to Danielle Peyton at Pomerantz for more information and guidance on their rights.

Recent Developments

The trigger for this investigation was a recent press release issued by PepGen on December 16, 2024, announcing that the company had received a clinical hold notice from the U.S. Food and Drug Administration (FDA). The notice pertains to PepGen’s Investigational New Drug (IND) application for the CONNECT2-EDO51 clinical trial, which is aimed at treating patients with Duchenne muscular dystrophy (DMD). The FDA indicated it would provide an official clinical hold letter within 30 days of this announcement.

Following the release of this alarming information, PepGen’s shares dropped sharply by $0.17, a decline of 3.63%, settling at $4.51 per share. This stock price drop reflects the market's response to potential delays and uncertainties surrounding the clinical trial process, which is crucial for the company's developmental pipeline and overall business performance.

The Role of Pomerantz LLP

Founded by the late Abraham L. Pomerantz, often referred to as the dean of class action law, Pomerantz LLP has built a legacy over its 85 years of fighting for the rights of investors. The firm is renowned for its successful pursuit of corporate accountability, especially in cases of securities fraud and breaches of fiduciary duty. The ongoing investigation into PepGen illustrates the firm’s commitment to protecting investor interests and ensuring that any potential misconduct is thoroughly examined.

Pomerantz has achieved numerous multimillion-dollar settlements on behalf of class members, reinforcing its position as a leader in this field. The firm operates across major cities, including New York, Chicago, and Los Angeles, and has a global footprint with offices in London, Paris, and Tel Aviv.

Next Steps for Investors

Investors who believe they may have been adversely affected by PepGen’s recent developments and the subsequent decline in share price should consider taking action. Pomerantz LLP invites affected parties to contact their office to discuss the possibility of joining the class action suit. Such collective actions can often provide a robust means to seek restitution for financial losses incurred.

Conclusion

Amidst the backdrop of increased regulatory scrutiny and the potential implications for PepGen's future, this investigation serves as a critical reminder of the complexities involved with investing in biopharmaceutical companies. Investors must remain vigilant and informed as developments unfold, especially concerning their rights and potential courses of action in light of this latest news. For further details, interested parties can contact Pomerantz directly.

For more information, please visit Pomerantz's official website.